Source: PR Newswire

Press Release: Morphotek : Morphotek And Rockefeller University Form A Sponsored Research Agreement To Study The Immunosuppressive Effects Of The Tumor Shed Antigen CA125 And Its Potential Impact In Future Patient Therapies

EXTON, Pa., Dec. 11, 2017 /PRNewswire/ -- Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has entered into a Sponsored Research Agreement (SRA) with The Rockefeller University to expand its research efforts around the mechanisms by which the CA125 tumor shed antigen...

Read full article »
Est. Annual Revenue
$25-100M
Agree?
Est. Employees
25-100
Agree?
CEO Avatar

CEO

Update CEO

CEO Approval Rating

- -/100

Read more